Clinical Trial Detail

NCT ID NCT03238196
Title Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Vanderbilt-Ingram Cancer Center
Indications

breast carcinoma

Therapies

Erdafitinib + Fulvestrant + Palbociclib

Age Groups: adult senior

Additional content available in CKB BOOST